Interim Report
January - June 2026

Acarix Second Quarter & First Half 2026 Summary

KEY Q2 TAKEAWAYS

Second quarter 2026 compared to the same period in 2025

- Total revenue amounted to SEK 2,308 thousand (1,140), an increase of 102%
- In the U.S., revenue amounted to SEK 1,857 thousand (595) and an increase by 212%
- Currency adjusted revenue increased by totally 108% and in US by 223%
- A total of 29 CADScor Systems (19) were delivered, an increase of 53%. 11 systems were consigned and 15 sold on the US market. 3 systems were sold outside the US market.
- A total of 182 boxes of patches (139) were sold, reflecting a 31% increase (1 box consist of 20 patches)
- In the U.S. patch sales amounted to 140 boxes (70), an increase of 100%
- Gross margin amounted to 84% (93%)
- Operating costs amounted to SEK 11,256 thousand (13,915), a decrease of 19%
- Net Loss was SEK -9,482 thousand (-12,863), an improvement of 26%
- Cash flow from operating activities was SEK -11,830 thousand (-12,666)
- Earnings per share were SEK -0.01 (-0.01)

First half of 2026 compared to the same period in 2025

- Total revenue amounted to SEK 4,732 thousand (2,870), an increase of 65%
- In the US, revenue amounted to SEK 3,867 thousand (1,829), an increase of 111%
- A total of 58 CADScor Systems (39) were delivered, an increase of 49%
- In the U.S. 55 CADScor Systems (38) were delivered, an increase of 45%
- A total of 354 boxes patches (297) were sold, an increase of 19%
- In the U.S. 262 boxes of patches (176) were sold, an increase of 49%
- Gross margin amounted to 83% (86%)
- Operating costs amounted to SEK 21,678 thousand (29,352), an improvement of 26%
- Net loss amounted to SEK -18,264 thousand (-26,971), an improvement of 27%
- Cash flow from operating activities was SEK -18,264 thousand (-26,971), an improvement of 32%
- Earnings per share amounted to SEK –0.02 (–0.02)
- Average number of shares amounted to 1,192,080 (1,123,744)

Significant Events during the Quarter

- Acarix presented its abstract at ACC.26, highlighting the diagnostic utility of the CADScor® System in comparison to standard stress tests for chest pain patients. Data demonstrated a high negative predictive value (NPV), with potential care time savings of up to 40 hours and cost reductions exceeding $100,000 per inpatient case. These findings reinforce the clinical and commercial viability of global adoption of the CADScor® System.

Significant events after June 30, 2026

- Acarix AB announced that the CADScor®System has received regulatory approval from the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP), clearing the way for commercial availability of the technology across the United Arab Emirates.

Comments from the CEO

The second quarter of 2026 was another period of strong commercial progress for Acarix compared to last year. Total revenue more than doubled compared with the same quarter last year while revenue in our core U.S. market rose by 212% to SEK 1,857 thousand — and by 223% when adjusted for currency effects. At the same time, we continued to operate a leaner organization, reducing operating costs by 19% and improving our net loss by 26% to SEK –9,482 thousand. These results reflect the balance we are working to strike between accelerating commercial growth and maintaining disciplined financial management.

The United States remains the primary engine of our growth and will continue to be our principal commercial focus. At the same time, we are encouraged by increasing international interest in the CADScor® System. As these opportunities develop, we will evaluate each market carefully to ensure that potential expansion is aligned with our overall strategic priorities and provides a clear path to effective commercial execution.
Building on our recent market approval in the United Arab Emirates (UAE), regulatory processes are also progressing in the Kingdom of Saudi Arabia (KSA) and Kuwait. We continue to work diligently to expand our international reach in a disciplined manner and expect to provide further updates on the progress and outcomes of these efforts throughout the remainder of 2026.

We also continued to strengthen the clinical evidence base for our technology. At ACC.26, the American College of Cardiology's annual scientific session, we presented data highlighting the diagnostic utility of the CADScor® System compared with standard stress testing for patients with chest pain. The findings demonstrated a high negative predictive value together with meaningful operational benefits, including potential care-time savings of up to 40 hours and cost reductions exceeding USD 100,000 per inpatient case. Evidence of this kind reinforces both the clinical and the commercial case for broader adoption of the CADScor® System worldwide.

Looking at the first half of the year, total revenue grew 65% to SEK 4,732 thousand, with U.S. revenue up 111%. Operating costs for the six months fell by 26% and our net loss improved by 27%, while a directed share issue further strengthened our cash position, which stood at SEK 28,883 thousand at the end of the period. Together, these developments have given us a firmer financial footing from which to pursue our growth plan. Our ambition is to see further positive development in the demand for CADScor® at an increasing pace enabling our cash position to last well into 2027.

As we move through the remainder of 2026 and into 2027, our focus remains firmly on disciplined execution and building the foundation for sustainable, long-term commercial growth. A key priority is converting our growing installed base of CADScor® Systems into deeper and more routine clinical utilization, while continuing to expand access across both existing and new markets.

In the U.S., reimbursement remains a central component of our commercial strategy. We continue to work diligently toward completing the clinical and evidentiary requirements necessary to support the transition from our current CPT Category III code to a CPT Category I code. We expect this work to support meetings with the Centers for Medicare & Medicaid Services (CMS) during the first half of 2027 regarding the CPT Category I transition. In parallel, we plan to engage with CMS during the first half of 2027 to pursue an increase in reimbursement for CADScor in the hospital outpatient setting.

Our clinical evidence base also continues to advance. We plan to submit our U.S. Performance Trial for publication before the end of 2026. Following submission, the peer review and publication process in the U.S. typically requires approximately three months, although timing can vary by journal.

Additionally, we expect greater visibility during Q3 2026 regarding the outcomes of our efforts related to the U.S. Rural Health Transformation Program (RHTP).
We believe the program represents an important potential opportunity to expand access to CADScor in rural communities while supporting broader adoption of point of care cardiovascular diagnostics.
Together, these initiatives, including greater utilization of our installed base, continued reimbursement progress, advancement toward CPT Category I, expansion of our clinical evidence, potential participation in RHTP, and broader market access, represent important building blocks in our strategy to translate the commercial momentum we have established into sustainable growth and long-term shareholder value.

I am encouraged by our performance in the second quarter and by the trajectory of the business through the first half of the year. Acarix is well positioned to continue expanding access to early, non-invasive cardiac diagnostics while creating lasting value for patients, providers, and shareholders.

Aamir Mahmood
President & CEO

Financial Reports

Profit/Loss Statements

Second quarter

The Group reported total revenue of SEK 2,308 thousand for the second quarter of 2026, representing a 102% increase from SEK 1,140 thousand in the same period last year. U.S. revenue amounted to SEK 1,857 thousand, up 212% from SEK 595 thousand. Currency-adjusted revenue increased by a total of 108%, with U.S. revenue adjusted for currency effects showing a 223% rise.

During the quarter, 29 CADScor Systems were delivered, a 53% increase from 19 units in the previous period. Of these, 11 systems were consigned and 15 sold within the U.S., while 3 systems were sold outside the U.S.
Patch sales totaled 182 boxes, up 31% from 139 boxes. U.S. patch sales reached 140 boxes, doubling from 70 boxes, representing a 100% increase.

The gross margin was 84%, compared to 93% in the previous period. The higher margin in the previous year was primarily driven by sales of patches, which have higher gross margins, while delivered systems were on consignment. This year's margin reflects a different sales mix, with sales of both systems and patches.
Operating costs decreased by 19% to SEK 11,256 thousand from SEK 13,915 thousand, reflecting ongoing cost efficiency efforts.

Net loss for the quarter improved to SEK –9,482 thousand from SEK –12,863 thousand, a 26% reduction.

First half year

Revenue for the period reached SEK 4,732 thousand, compared to SEK 2,870 thousand for the same period last year, reflecting a 65% increase. In the U.S., revenue amounted to SEK 3,867 thousand, up 111% from SEK 1,829 thousand. This growth is driven by increased sales in the US market.

A total of 58 CADScor Systems were delivered during the period, representing a 49% increase from 39 units last year. Specifically in the U.S., 55 systems were delivered, up 45% from 38 units.

Patch sales totaled 354 boxes, an increase of 19% from 297 boxes, with 262 boxes sold in the U.S., up 49% from 176 boxes.

Gross margin was 83%, slightly down from 86% in the previous year, mainly due to product mix.

Total operating costs decreased to SEK 21,678 thousand from SEK 29,352 thousand, an improvement of 26%, reflecting ongoing cost optimization efforts.

The net loss for the period was SEK -18,264 thousand, an improvement of 32% from SEK -26,971 thousand in the same period last year, indicating positive progress in our financial performance.

Financial Position Overview

Tangible assets amounted to SEK 195 thousand, representing the net value of CADScor Systems held under the consignment model in the U.S. market. Intangible assets, including the net value of patents and development costs, totaled SEK 5,260 thousand, a decrease from SEK 8,011 thousand as of June 2025. No intangible asset acquisitions were made during the period.

Inventory was valued at SEK 6,127 thousand, reflecting a 16% decline from SEK 7,277 thousand in June 2025. The company's cash balance stood at SEK 28,883 thousand, compared to SEK 32,260 thousand as of June 2025. The company's cash balance has been strengthened during the period through a directed share issue.

As of June 30, the company's equity stood at SEK 43,776 thousand, down from SEK 47,728 thousand as of June 2025. The share capital was SEK 12,405 thousand, with a total of 1,240,511,582 shares registered with the Swedish Companies Registration Office.

Total current liabilities decreased to SEK 3,963 thousand from SEK 5,153 thousand as of June 2025.

Cash Flow and Financing

Second quarter
In the second quarter, the company's cash flow from operating activities was negative, totaling SEK -11,830 thousand, compared to SEK -12,666 thousand in the same period last year. This negative cash flow reflects an operational loss along with changes in working capital.

Working capital adjustments resulted in a net outflow of SEK -3,356 thousand, driven primarily by a decrease in trade and other payables contributed a cash outflow of SEK -2,823 thousand and an increase in receivables and prepayments of SEK -726 thousand.

Investing activities saw an outflow of SEK -339 thousand, attributable to consignments of CADScor Systems, consistent with the prior year's same period.

In financing activities, the company recognized SEK 15,054 thousand from the direct issue after deduction of transaction costs, contributing to a positive cash inflow of the same amount.

Overall, the company's cash flow for the second quarter was SEK 2,885 thousand, resulting in an ending cash balance of SEK 28,883 thousand.

First half year
During the first half of 2026, the company's cash flow from operating activities was SEK -10,717 thousand, an improvement compared to SEK -24,332 thousand in the same period last year. This reduction in cash outflow reflects tighter cost controls and more efficient working capital management.

The total change in working capital was SEK 5,885 thousand, driven by an increase in receivables and prepayments of SEK 10,751 thousand. Under the item Changes in receivables and prepayments SEK 11,793 thousand was included as a receivable from the share issuance bank, which as of December 2025 was holding liquid funds for registered shares in the ongoing directed issue. The payment was made to the company during January 2026. The net cash flow from operating activities was SEK -10,717 thousand for the period.

In financing activities, the company issued SEK 20,938 thousand after deduction of transaction costs from the directed issue.

Overall, the cash flow for the first six months was SEK 10,062 thousand, ending with a cash balance of SEK 28,883 thousand as of June 30, 2026.

Financing

At the start of the fourth quarter of 2025, the Board approved a directed share issue aimed at U.S. and Nordic investors, with an expected gross raise of approximately SEK 33.4 million before issuance costs. By June 30, 2026, the full amount of SEK 33.4 million had been received into the company's share issue account. As of June 30, 2026, the process of delivering shares to the U.S. investors was still ongoing.

The Board of Directors and executive management work continuously to secure the company's long-term financing to ensure the operation of the business. The company's growth plan is continuously balanced against the financial resources available at any given time. The established growth plan, which is driven by market demand, may require additional financing during first quarter of 2027, which could be obtained through, for example, loans or share issuance.

The Parent Company

The Parent Company is primarily responsible for the financial management of the Group. The company reported a net loss of SEK -8,113 (-11,433) thousand, primarily due to a SEK -8,184 (-10,669) thousand write-down and expense of shareholder contributions to subsidiaries, which are reflected as a financial item in the parent company's income statement. As of June 30, shares in subsidiaries amounted to SEK 44,592 thousand (44,868). The Parent Company's cash and cash equivalents on June 30 were SEK 23,766 thousand, compared to SEK 15,577 thousand in June 30 previous year.

Auditor's Review

This interim report has not been reviewed by the company's auditor.

Certified Advisor

The Company's Certified Adviser is Tapper Partners AB

Financial Reports

Shareholder Register June 30, 2026

Shareholder register June 30, 2026	Number of shares	Votes and capital
Avanza Pension	78,943,030	20.1%
Pagidipati Murthy Investments LLC	60,915,416	4.9%
RFR Holdings II LLC	58,437,721	4.7%
Jan Sören Poulsen	42,612,476	3.4%
Carl Johan Mikael Fröjden-Thoren	33,934,547	2.7%
JAJS Management	26,654,513	2.2%
Filip Fröjdén	26,106,511	2.1%
Vonu Enterprises LLC	21,494,460	1.7%
Microtech Software A/S	20,513,884	1.7%
LLC Brookbo Investments	18,661,374	1.5%
10 largest owners	**388,273,932**	**31.3%**
Other owners	**852,237,650**	**68.7%**
Total as of June 30, 2026	**1,240,511,582**	**100.0%**

Financial Calendar

Interim Report Q2, August 13, 2026
Interim Report Q3, November 5, 2026
Interim Report Q4, February 11, 2027

For more information, please contact

Christian Lindholm
CFO
Email: christian.lindholm@acarix.com

Group - Consolidated Statement of Income

kSEK	Note	April - June 2026	April - June 2025	January-June 2026	January-June 2025	Year 2025
Revenue	7	2,308	1,140	4,732	2,870	7,361
Cost of goods sold		-370	-72	-826	-396	-1,123
Gross profit		**1,938**	**1,068**	**3,906**	**2,473**	**6,238**
Research and development costs		-2,366	-3,985	-4,549	-8,276	-14,755
Sales, general and administrative costs		-8,890	-9,930	-17,129	-21,076	-39,495
Operating profit		**-9,318**	**-12,847**	**-17,772**	**-26,879**	**-48,012**
Financial income		4	34	89	88	406
Financial costs		-168	-49	-581	-188	-485
Profit before tax		**-9,482**	**-12,863**	**-18,264**	**-26,971**	**-48,091**
Tax		-	-	-	-	-
Net loss for the year		**-9,482**	**-12,863**	**-18,264**	**-26,971**	**-48,091**
Net income attributable to parent company's shareholders		**-9,482**	**-12,863**	**-18,264**	**-26,971**	**-48,091**
Basic earnings per share (SEK) (1)		-0.01	-0.01	-0.02	-0.02	-0.04
Diluted earnings per share (SEK)		-0.01	-0.01	-0.02	-0.02	-0.04
Average number of shares, before dilution (thousands)		1,211,861	1,123,744	1,192,080	1,123,744	1,126,768
Average number of shares, after dilution (thousands)		1,211,861	1,123,744	1,192,080	1,123,744	1,126,768

1) EPS – Net profit for the period, attributable to shareholders of the Parent Company, divided by average number of shares outstanding.

Group - Consolidated Statement of Comprehensive Income

kSEK	Note	April-June 2026	April-June 2025	January-June 2026	January-June 2025	Year 2025
Net loss for the year after tax		-9,482	-12,863	-18,264	-26,971	-48,091
Items that may be reclassified to profit or loss						
Foreign currency translation adjustment		131	-1,962	694	-4,124	-2,774
Other comprehensive income for the year, net of tax		**131**	**-1,962**	**694**	**-4,124**	**-50,865**
Total comprehensive income for the year, net of tax		-9,351	-14,825	-17,570	-31,095	-50,865
Total comprehensive income attributable to:						
Owners of Acarix		-9,351	-14,825	-17,570	-31,095	-50,865

Group - Consolidated Statement of Financial Position

kSEK	Note	June 30 2026	June 30 2025	Year 2025
Assets				
Tangible assets				
Tangible assets		195	402	372
Total tangible assets		195	402	372
Intangible assets				
Acquired rights		3,044	3,345	3,119
Development projects, capitalized		2,216	4,665	3,356
Total intangible assets		**5,260**	**8,011**	**6,475**
Current assets				
Inventory		6,127	7,277	6,460
Accounts receivables		5,406	1,937	2,179
Other receivables		1,868	2,994	14,570
Cash and cash equivalents	8	28,883	32,260	18,274
Total current assets		42,284	44,468	41,483
Total assets		47,739	52,881	48,330
Shareholders's equity and liabilities				
Equity				
Share capital		12,405	11,233	11,647
Other contributed capital		706,449	675,272	686,269
Reserves		3,135	3,253	2,441
Retained earnings		-659,948	-615,059	-614,095
Result for the year		-18,264	-26,971	-48,091
Total equity		**43,776**	**47,728**	**38,171**
Current liabilities				
Accounts payable		1,058	1,874	3,108
Other liabilities		2,905	3,279	7,051
Total current liabilities		**3,963**	**5,153**	**10,159**
Total equity and liabilities		**47,739**	**52,881**	**48,330**

Group - Consolidated Statement of Changes In Equity

kSEK	Share capital	Share premium	Other reserved	Retained earnings & result of the year	Total shareholders equity
As at 1 January 2026	**11,647**	**686,269**	**2,441**	**-662,186**	**38,171**
Profit/loss for the year				-18,264	-18,264
Other comprehensive income:					
Foreign exchange rate adjustment			694		694
Total	**11,647**	**686,269**	**3,135**	**-680,450**	**20,601**
Transactions with owners:					
Issue of warrants				2,238	2,238
Ongoing Share issue	758	20,849			21,607
Costs related to share issue		-669			-669
At June 30 2026	**12,405**	**706,449**	**3,135**	**-678,212**	**43,776**

kSEK	Share capital	Share premium	Other reserved	Retained earnings & result of the year	Total shareholders equity
As at 1 January 2025	**11,233**	**675,272**	**5,215**	**-616,023**	**75,697**
Profit/loss for the year				-26,971	-26,971
Other comprehensive income:					
Foreign exchange rate adjustment			-1,962		-1,962
Total	**11,233**	**675,272**	**3,253**	**-642,994**	**46,764**
Transactions with owners:					
Issue of warrants				964	964
At June 30 2025	**11,233**	**675,272**	**3,253**	**-642,030**	**47,728**

Group - Consolidated Statement of Cash Flow

kSEK	Note	April - June 2026	April - June 2025	January-June 2026	January-June 2025	Year 2025
Operating activities						
Operating result		-9,318	-12,847	-17,769	-26,879	-48,012
Adjustment for depreciation		1,008	847	1,660	1,739	3,477
Financial items		-164	-16	-492	-92	-79
Cash-flow before change of working capital		**-8,474**	**-12,016**	**-16,602**	**-25,232**	**-44,613**
Working capital adjustments:						
Change in inventory		193	-834	401	-187	623
Change in receivables and prepayments		-726	9	10,751	494	13,266
Change in trade and other payables		-2,823	175	-5,267	593	-6,554
Total change in working capital		**-3,356**	**-650**	**5,885**	**900**	**7,335**
Cash -flow from operating activities		**-11,830**	**-12,666**	**-10,717**	**-24,332**	**-37,278**
Investing activities						
Investment in fixed assets		-339	-361	-159	-462	-757
Cash-flow from investing activities		**-339**	**-361**	**-159**	**-462**	**-757**
Financing activities						
Rights issue after deduction of transaction costs		15,054	-	20,938	-	-
Cash flow from financing activities		**15,054**	**-**	**20,938**	**-**	**-**
Cash flow for the year		**2,885**	**-13,027**	**10,062**	**-24,794**	**-38,035**
Currency translation differences		205	239	547	-1,561	-2,306
Cash and cash equivalents, beginning of year		25,793	45,048	18,274	58,615	58,615
Cash and cash equivalents, end of year		**28,883**	**32,260**	**28,883**	**32,260**	**18,274**

Parent Company - Income Statement

kSEK	Note	April - June 2026	April - June 2025	January-June 2026	January-June 2025	Year 2025
Other revenues		**2,100**	**500**	**4,200**	**3,500**	**8,310**
Sales, general and administrative costs		-1,857	-1,264	-3,988	-3,348	-15,701
Operating result		**243**	**-764**	**212**	**152**	**-7,391**
Profit / Loss from shares in group companies		-8,184	-10,669	-14,208	-27,297	-33,776
Financial income		-	-	-	-	330
Financial expense		-172	-	-563	-	-
Profit before tax		**-8,113**	**-11,433**	**-14,558**	**-27,145**	**-40,837**
Tax		-	-	-	-	-
Net loss for the year		**-8,113**	**-11,433**	**-14,558**	**-27,145**	**-40,837**
Net income attributable to Parent Company´s Shareholder		**-8,113**	**-11,433**	**-14,558**	**-27,145**	**-40,837**

Parent Company - Balance Sheet

kSEK	Note	June 30 2026	June 30 2025	Dec 31 2025
Financial assets				
Participations in subsidiaries		44,592	44,868	44,592
Total financial assets		**44,592**	**44,868**	**44,592**
Current assets				
Other receivables		486	4,346	12,630
Intercompany receivables		928	-	-
Cash and cash equivalents	8	23,766	17,577	14,031
Total current assets		**25,180**	**21,923**	**26,661**
Total assets		**69,772**	**66,791**	**71,253**
Shareholders' equity and liabilities				
Equity				
Share capital		12,405	11,233	11,647
Other capital contribution		490,344	459,167	470,164
Retained earnings		-434,975	-406,725	-420,417
Total equity		**67,774**	**63,675**	**61,394**
Current liabilities				
Accounts payable		565	116	1,069
Intercompany payables		-	1,789	2,710
Other liabilities		1,432	1,210	6,080
Total current liabilities		**1,997**	**3,115**	**9,859**
Total equity and liabilities		**69,772**	**66,791**	**71,253**

Parent Company - Consolidated Statement of Change In Equity

kSEK	Share capital	Share premium	Retained earnings & result of the year	Total shareholders equity
As at 1 January 2026	11,647	470,164	-420,417	61,394
Profit/loss for the year			-14,558	-14,558
Total comprehensive income	**11,647**	**470,164**	**-434,975**	**46,836**
Transactions with owners:				
Ongoing share issue	758	20,849		21,607
Costs related to share issue		-669		-669
Total transactions with owners	**758**	**20,180**		**20,938**
At June 30, 2026	**12,405**	**490,344**	**-434,975**	**67,774**

kSEK	Share capital	Share premium	Retained earnings & result of the year	Total shareholders equity
As at 1 January 2025	11,233	459,167	-379,580	90,820
Profit/loss for the year			-27,145	-27,145
Total comprehensive income	**11,233**	**459,167**	**-406,725**	**63,675**
At June 30, 2025	**11,233**	**459,167**	**-406,725**	**63,675**

Notes

Note 1 Corporate Information

Company Information

Acarix AB (559009-0667) is a limited liability company incorporated and domiciled in Malmö, Sweden. The registered office is located at Regus, Hyllie Boulevard 34, 215 32 Malmö, Sweden. Acarix's main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services.

The Acarix Group Consists of:		
Acarix A/S	The main operating company	Incorporated and located in Denmark
Acarix GmbH	Supporting sales on the German market (under liquidation)	Incorporated and located in Germany, under liquidation
Acarix Inc	Supporting sales on the US market	Incorporated and located in USA
Acarix Ltd	Supporting sales on the UK market	Incorporated and located in UK

Note 2 Basis of Preparation

The interim report for the Group and Parent Company comprises summary consolidated financial statements for Acarix AB (publ). The interim consolidated financial statements include the Company's wholly-owned subsidiaries according to above specification.

Note 3 Accounting Policies

The consolidated report has been prepared in accordance with International Financial Reporting Standards (IFRS) and IAS 34, Interim Financial Reporting. Acarix continues to apply the same accounting principles and valuation methods as those described in the most recent annual report. The Parent Company report is prepared in accordance with RFR 2, Accounting for Legal Entities, the Swedish Annual Accounts Act and accounting principles and the valuation methods as those described in the most recent annual report.

Note 4 Significant Accounting Policies, Judgments and Assumptions

In preparing the interim report, certain provisions under IFRS require management to make judgments, which may significantly impact the group's financial statements. For additional descriptions of significant judgments and estimates, refer to note 4 in the annual report 2025.

Note 5 Risk Management

The Acarix Group is exposed to business and financial risks through its operations. These risks have been described at length in the company's annual report 2025. In addition to the risks described in these documents, no additional significant risks have been identified.

Note 6 Related Parties

Related parties comprise the members of the Board of Directors and other senior executives. Apart from remuneration of the Board of Directors, a board member of the company has performed consulting services outside of their board assignment in accordance with a signed consulting agreement, amounting to SEK 147,938. The transactions have been conducted on market terms.

Note 7 Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the group and the revenue can be reliably measured, regardless of when the payment is received. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duty. The specific recognition criteria described below must also be met before revenue is recognized.

Sale of goods

Revenue from the sale of goods is recognized when the significant control of ownership of the goods has passed to the buyer, usually on delivery of the goods. Revenue from the sale of goods is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates.

Revenues from agreements with customers

Revenue 2026	Q1	Q2	Q3	Q4	2026
USA	2,010	1,857			3,867
Germany	339	351			690
Sweden	75	44			119
Other	-	56			56
Total	2,424	2,308	0	0	4,732

Revenue 2025	Q1	Q2	Q3	Q4	2025
USA	1,235	595	766	1,792	4,388
Germany	366	530	231	319	1,446
Sweden	128	16	-	30	174
Iraq	-	-	1,353	-	1,353
Other	-		-	-	30
Total	1,729	1,141	2,350	2,141	7,361

Note 8 Guarantees

During the quarter, the Group issued a bank guarantee to a subcontractor for the supply of components related to CADScorSystem. As of June 30, 2026, this bank guarantee amounts to SEK 2,960 thousand (DKK 2,000 thousand). There are no other significant changes to the Group’s contingent liabilities compared to those disclosed in the Annual Report for 2025.

Affirmations

This interim report has been prepared in accordance with International Accounting Standard (IAS) 34 “Interim Financial Reporting” and in accordance with the Swedish Annual Accounts Act. With respect to the Parent Company, this interim report has been prepared in accordance with the Swedish Annual Accounts Act and in compliance with RFR2, Accounting for Legal Entities. The Board of Directors and the CEO certify that this interim report presents a true and fair overview of the Group’s and the Parent Company’s operations, financial position and results of operations, and describes the significant risks and uncertainties facing the Parent Company and the companies belonging to the group.

August 13, 2026

Executive Management

Aamir Mahmood
President & CEO

Board of Directors

Jan Poulsen
Chairman of the Board

Tony Das
Board Member

Kenneth Nelson
Board Member

Erik von Schenck
Board Member

Marcin Gołębicki
Board Member

Leadership

Aamir Mahmood
President & CEO

Christian Lindholm
Chief Financial Officer

Carma Connely
Head of Operations & Customer Excellence

Beji George
Head of Global Strategy & Therapy Development

Daniel Burke
Head of Reimbursement & Market Access

George Chrysant, MD
Chief Medical Adviso

Hyllie Boulevard 34, 5TR
SE- 215 32 Malmö
info@acarix.com
www.acarix.com